Jounce Therapeutics

Biotech layoffs gather pace as industry downturn persists
Biotech layoffs gather pace as industry downturn persists
BioPharma Dive
layoffs
biotech
Amgen
Pfizer
Roche
Jounce Therapeutics
Fate Therapeutics
Molecular Templates
Sorrento Therapeutics
Flag link:
Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs
Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs
Yahoo/Reuters
Jounce Therapeutics
M&A
Concentra Biosciences
layoffs
Flag link:
Concentra's Buy Offer May Jeopardize Jounce's Merger with Redx
Concentra's Buy Offer May Jeopardize Jounce's Merger with Redx
BioSpace
Jounce Therapeutics
Redx
Concerta
M&A
Flag link:
Jounce Slashes 57% of Staff, Drops Assets in Stock Merger with Redx
Jounce Slashes 57% of Staff, Drops Assets in Stock Merger with Redx
BioSpace
Jounce Therapeutics
Redx
M&A
layoffs
Flag link:
Conditions are ripe for reverse mergers
Conditions are ripe for reverse mergers
EP Vantage
M&A
reverse merger
Redx
Jounce Therapeutics
Pherecydes
Erytech
Flame Biosciences
Leap Therapeutics
Elicio Therapeutics
Angion
Flag link:
Gilead buys remaining rights to Jounce’s immunotherapy GS-1811
Gilead buys remaining rights to Jounce’s immunotherapy GS-1811
Medical Marketing and Media
Gilead Sciences
Jounce Therapeutics
GS-1811
Flag link:
Jounce’s latest setback dampens outlook for another cancer immunotherapy target
Jounce’s latest setback dampens outlook for another cancer immunotherapy target
BioPharma Dive
Jounce Therapeutics
lung cancer
cancer immunotherapy
vopratelimab
Flag link:
Final Highlights from the 2021 J.P. Morgan Healthcare Conference
Final Highlights from the 2021 J.P. Morgan Healthcare Conference
BioSpace
JPMHC 2021
intravenous immunoglobulin
IDEAYA Biosciences
Jounce Therapeutics
Puma Biotechnology
Flag link:
Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
BioSpace
Jounce Therapeutics
vopratelimab
Santhera
vamorolone
Puldysa
Aurinia Pharmaceuticals
FOS
Flag link:
Jounce shares crash after it abandons immunotherapy combination trial
Jounce shares crash after it abandons immunotherapy combination trial
Pharmaforum
Jounce Therapeutics
non-small cell lung cancer
Bristol-Myers Squibb
Yervoy
Flag link:
After Bristol snub, Gilead pens $120M upfront, $685M in biobucks for early Jounce cancer program
After Bristol snub, Gilead pens $120M upfront, $685M in biobucks for early Jounce cancer program
Fierce Biotech
Jounce Therapeutics
Gilead Sciences
Bristol-Myers Squibb
biobucks
immuno-oncology
Flag link:
Bristol's Celgene merger sees it bounce Jounce drug pact
Bristol's Celgene merger sees it bounce Jounce drug pact
Fierce Biotech
Bristol-Myers Squibb
Celgene
Jounce Therapeutics
M&A
immuno-oncology
Flag link:
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
Yahoo/Benzinga
earnings
Forty Seven
Jounce Therapeutics
Catalyst Biosciences
Kodiak Sciences
Adverum Biotechnologies
IPOs
Beam Therapeutics
Flag link:
Why wait? Celgene restructures a big Jounce pact — zeroing in on new I/O pathway with $530M deal and bumping ICOS
Why wait? Celgene restructures a big Jounce pact — zeroing in on new I/O pathway with $530M deal and bumping ICOS
Endpoints
Celgene
Jounce Therapeutics
JTX-8064
macrophages
Flag link:
Jounce seeking tumor-agnostic approach for ICOS agonist
Jounce seeking tumor-agnostic approach for ICOS agonist
BioCentury
Jounce Therapeutics
ICOS agonist
JTX-2011
Flag link:
Smaller groups await Bristol-Myers Squelgene fallout
Smaller groups await Bristol-Myers Squelgene fallout
EP Vantage
M&A
Bristol-Myers Squibb
Celgene
Vividion Therapeutics
Evotec
Prothena
Anokion
Skyhawk Therapeutics
Dragonfly Therapeutics
BeiGene
Agios Pharmaceuticals
Jounce Therapeutics
Flag link:
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Xconomy
Celgene
M&A
Juno Therapeutics
Kite Therapeutics
Bluebird Bio
Agios Pharmaceuticals
Jounce Therapeutics
BieGene
Acceleron
Flag link:
ASCO18: Jounce plummets further on weak efficacy data
ASCO18: Jounce plummets further on weak efficacy data
Biopharma Dive
Jounce Therapeutics
ASCO 2018
JTX-2011
solid tumors
Flag link:
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Flag link:
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Motley Fool
ASCO
Endocyte
Loxo Oncology
Blueprint Medicines
Nektar Therapeutics
Jounce Therapeutics
Flag link:

Pages